To evaluate the association between high estimated pulmonary artery systolic pressure (ePASP) obtained by echocardiography and 1-year mortality in patients with acute heart failure (HF), comparing findings in individuals aged 80 and older with those of individuals younger than 80. DESIGN: Retrospective cohort study. SETTING: Kyorin University Hospital. PARTICIPANTS: Individuals with acute decompensated HF (N = 335). MEASUREMENTS: High ePASP was defined as a tricuspid regurgitation pressure gradient greater than 47 mmHg (ePASP >50 mmHg). Potential risk factors for 1-year mortality were selected using univariate analysis followed by multivariate Cox regression analysis with backward stepwise selection of variables with P < .10 on univariate analysis to identify significant factors. RESULTS: In individuals aged 80 and older, high ePASP (hazard ratio (HR)=3.07; 95% confidence interval (CI) =1.21-7.80), discharge medications without diuretics (HR=4.18, 95% CI=1.66-10.54), and discharge medications without renin-angiotensin-aldosterone system inhibitors (HR=3.38, 95% CI=1.29-8.81) were independent risk factors for 1-year mortality. In contrast, low systolic blood pressure at admission was the sole independent risk factor for 1-year mortality (HR=0.94, 95% CI=0.89-0.99) in those younger than 80. CONCLUSION: High ePASP is a significant predictor of 1-year mortality in individuals aged 80 and older with acute HF but not in those younger than 80. Elucidation of the pathophysiological mechanisms behind these findings should facilitate the development of more effective individualized therapies for older adults with acute HF. J Am Geriatr Soc 67:323-328, 2019.
W
ith the progressive aging of the population, the number of older-elderly patients with acute heart failure (HF) is increasing. 1 To extend healthy life expectancy, understanding the pathophysiology of HF and improving its treatment in older-elderly patients are important. Nevertheless, these individuals are often underrepresented in or excluded from large clinical trials, [2] [3] [4] [5] and the characteristics of HF in the older-elderly are ill defined. Older-elderly patients have a clinical profile different from that of younger individuals, and of note, pulmonary artery systolic pressure (PASP) is reported to increase with age. 6 Right-sided cardiac catheterization allows direct measurement of PASP, but there has been a reduction in hemodynamic assessments using this technique because of its invasive nature. Instead, Doppler echocardiography is frequently used to estimate PASP noninvasively.
Pulmonary hypertension is an emerging cardiovascular risk factor in the general population, [7] [8] [9] [10] but the results of previous studies of the association between pulmonary hypertension and outcomes in individuals with HF are contentious. [11] [12] [13] [14] This could reflect differences in participant background and disease conditions. Lam et al. 6 suggested that increasing pulmonary artery pressure with age was related, at least in part, to age-associated vascular stiffening and pulmonary venous hypertension from left ventricular (LV) diastolic dysfunction. It is possible that the prognostic value of a high estimated PASP (ePASP) obtained using echocardiography in individuals with HF could differ according to age. Therefore, in the present study, we compared the association between high ePASP and 1-year mortality in individuals with acute HF aged 80 and older and those younger than 80.
METHODS

Study Population
We retrospectively studied 335 consecutive individuals admitted for acute decompensated HF to Kyorin University Hospital, Japan, from March 2009 to August 2013. Individuals with acute coronary syndrome, hemodialysis, idiopathic pulmonary arterial hypertension, or pulmonary embolism were excluded from the study, as were those for whom there was no information regarding the maximum tricuspid regurgitation pressure gradient (TRPG) measured using echocardiography. A past history of hypertension, dyslipidemia, diabetes mellitus, chronic obstructive pulmonary disease, or HF was determined from interviews with the individual or his or her family during past health examinations, diagnoses made by family doctors, or a combination thereof.
The institutional ethics review board of Kyorin University School of Medicine approved this study.
Echocardiographic Parameters
PASP was estimated using Doppler echocardiography from the maximum TRPG: ePASP = TRPG + right atrial pressure. Because right atrial pressure was assumed to be 3 to 15 mmHg, 15 and a high ePASP was regarded as an ePASP greater than 50 mmHg, 16 high ePASP was defined as a TRPG of greater than 47 mmHg in the present study. LV ejection fraction (LVEF) was determined using the modified biplane Simpson's method. 17 The peak velocities of early (E) and late (A) mitral flow and the deceleration time of the E wave were measured using pulsed-wave Doppler with the sample volume at the tip of the mitral valve leaflets. Pulsedwave tissue Doppler imaging was applied to the apical 4-chamber view to determine the early (E 0 ) and late (A 0 ) velocities. The peak early diastolic myocardial velocities at the septal and lateral annuli were measured and averaged to calculate mean E 0 . The peak velocities of E and A, deceleration time, and the E/E 0 ratio were not measured if the individual had undergone mitral valve replacements or repairs. The E/A ratio was not calculated if the individual had atrial fibrillation or flutter.
Statistical Analysis
Continuous data were assessed for normality using the Shapiro-Wilk test. Normally distributed continuous variables, presented as means AE standard deviations, of participants aged 80 and older were compared with those of participants younger than 80 using the unpaired t-test or the Welch test depending on the results of the Levene test for homoscedasticity. Continuous variables that were not normally distributed, presented as medians with interquartile ranges, were compared between groups using the Mann-Whitney test. Categorical data are presented as percentages and were compared using the chi-square or Fisher exact test, as appropriate. Kaplan-Meier survival curves and log-rank testing were used to compare all-cause 1-year mortality of the groups. Potential risk factors for all-cause 1-year mortality were selected using univariate analyses; then multivariate Cox regression analysis with backward stepwise selection was performed for variables with a statistical value of P < .10 in univariate analyses to identify significant factors. All statistical analyses were performed using SPSS version 22 (IBM Japan, Tokyo, Japan). P < .05 was considered significant. Table 1 details the clinical characteristics of study participants. Of the entire study cohort, 45% were aged 80 and older and 55% were younger than 80. Those aged 80 and older had significantly higher rates of atrial fibrillation or flutter, prevalence of hypertension, and past history of HF than those younger than 80 and significantly higher plasma B-type natriuretic peptide levels, LVEF, and blood urea nitrogen (BUN) levels. Conversely, those aged 80 and older were significantly less likely to be male and have a past history of diabetes mellitus and smoking than those younger than 80 and had a significantly lower body mass index, hemoglobin level, glycosylated hemoglobin, left atrial (LA) diameter, and E/A ratio. There were no significant differences between the age groups in systolic blood pressure (SBP) at admission, heart rate, white blood cell count, creatinine, admission blood glucose level, or E/E 0 ratio (Table 1) . Estimated glomerular filtration rate (eGFR; mL/min per 1.73 m 2 ) was calculated using the Japanese GFR equation based on serum creatinine, 18 and participants with Stage 3 or greater chronic kidney disease (eGFR <60 mL/min per1.73 m 2 ) were identified. 19 The proportion of participants with Stage 3 or greater chronic kidney disease was significantly higher in those aged 80 and older than in those younger than 80 (72% vs 59%, P = .009). With regard to LVEF, we further divided the population into those with HF with reduced EF (HFrEF, LVEF <40%), HF with midrange EF (HFmrEF, LVEF 40-49%), and HF with preserved EF (HFpEF, LVEF ≥50%) 20 and examined the proportion with either disease state according to age. Participants aged 80 and older were significantly more likely to have HFpEF and less likely to have HFrEF than those younger than 80 (Supplementary Table S1 ). The rate of HFmrEF did not differ significantly according to age.
RESULTS
We also evaluated medications at discharge. Prescription rates for diuretics, renin-angiotensin-aldosterone system inhibitors (RAASIs), beta blockers, and calcium channel blockers at discharge did not differ significantly according to age (Table 2 ).
All-cause 1-year mortality (overall, 10.4%) was significantly higher in participants aged 80 and older (17.2%) than in those younger than 80 (5.4%) (P = .001).
Univariate Cox regression analyses revealed that high creatinine (P = .01), BUN (P = .02), and plasma B-type natriuretic peptide (P = .04) levels at admission; high ePASP (P = .004); and discharge medications without diuretics (P = .02), RAASI (P = .004), or beta blockers (P = .002) were all potential risk factors for 1-year mortality in participants aged 80 and older (Table 3 ). An eGFR of less than 60 mL/min per 1.73 m 2 was not found to be a potential risk factor (P = .82). Subsequent multivariate Cox regression analysis with backward stepwise selection using variables with P < .10 in the univariate analyses identified high ePASP (hazard ratio (HR), 3.07, 95% confidence interval (CI) = 1.21-7.80; P = .02), discharge medications without diuretics (HR = 4.18, 95% CI = 1.66-10.54, P = .002), and discharge medications without RAASI (HR = 3.38, 95% CI = 1.29-8.81, P = .01) as significant risk factors for 1-year mortality in those aged 80 and older (Table 4) .
For participants younger than 80, univariate Cox regression analyses revealed that older age (P = .09), past history of hypertension (P = .06), low SBP at admission (P = .04), low heart rate at admission (P = .03), high BUN level at admission (P = 0.064), low LVEF (P = .07), and discharge medications without beta blockers (P = .07) were potential risk factors for 1-year mortality (Table 3 ). An eGFR of less than 60 mL/min per 1.73 m 2 was not identified as a potential risk factor (P = .96). Subsequent multivariate Cox regression analysis with backward stepwise selection for variables of P < .10 in the univariate analyses showed that low SBP at admission was the sole significant risk factor for 1-year mortality (HR = 0.94, 95% CI=0.89-0.99, P = .02) in participants younger than 80.
The timing of the echocardiography study within the hospitalization period was assessed by calculating the interval between admission and echocardiography according to the formula [(date of echocardiography) -(date of hospital admission)], and the interval did not differ significantly between participants who survived and those who did not in participants aged 80 and older (median 3 days, interquartile range (IQR) 0-8 days vs median 5 days, IQR 1-10 days, respectively; P = .25) or those younger than 80 (median 4, IQR 1-10 days vs median 3 days, IQR 1-10 days, respectively; P = .59). The rate of high ePASP did not differ significantly between those aged 80 and older (11%) and those younger than 80 (13%) (P = .70) ( Table 1) . Of participants younger than 80, 9% had moderately high ePASP (defined as 50 < ePASP ≤ 70 mmHg, i.e., 47 < TRPG ≤ 67 mmHg), and 4% had severely high ePASP (defined as an ePASP > 70 mmHg, i.e., TRPG > 67 mmHg); of those aged 80 and older, 11% had moderately high ePASP and none had severely high ePASP. TRPG analyzed as a continuous variable did not differ significantly between participants aged 80 and older (median 29, IQR 23-40 mmHg) and those younger than 80 (median 31, IQR 25-40 mmHg) (P = .15). Importantly, there were significant differences between the 2 groups in terms of high ePASP as a prognostic factor for 1-year mortality. In the case of participants aged 80 and older, 1-year mortality was significantly higher for individuals with a high ePASP than those without an elevated ePASP ( Figure 1A ; log-rank, P = .002). On the other hand, participants younger than 80 with high ePASP did not have bad outcomes, and their 1-year mortality did not differ significantly from those without a high ePASP ( Figure 1B ; log-rank, P = .86).
DISCUSSION
The present study demonstrates that high ePASP is a significant predictor of all-cause 1-year mortality in individuals with HF aged 80 and older but not in those younger than 80, suggesting different underlying pathophysiologies between these groups. Multivariate Cox regression analysis with backward stepwise elimination was conducted in participants aged ≥80 with heart failure.
At present most individuals with HF are elderly because of the progressive aging of the population. 1 In the past, individuals aged 65 and older were regarded as elderly, but given the aging of the population, the cut-off for the elderly age bracket has been shifting toward 70 to 80 recently. 5, [21] [22] [23] [24] In the present study, we focused on individuals aged 80 and older. Importantly, these aged patients are often underrepresented in or excluded from large clinical trials. [2] [3] [4] [5] Although individuals aged 80 and older have a significantly worse prognosis, pathophysiological differences between them and those younger than 80 with HF remain ill defined.
Pulmonary hypertension is an emerging cardiovascular risk factor in the general population, 7-10 but whether a high PASP is an independent prognostic factor in HF remains contentious, and estimates of PASP have not been included in major HF risk prediction models. [25] [26] [27] Some studies have shown an association between high ePASP and mortality in HF, 11, 12 whereas others have failed to demonstrate the prognostic significance of pulmonary hypertension in HF. 13, 14 These discrepancies might be related to the different clinical situations in these studies, and careful interpretation of each study is needed. HF is a heterogeneous group of conditions with multiple pathophysiological factors, and previous studies examining the prognostic significance of pulmonary hypertension in HF have been conducted using variable definitions of pulmonary hypertension. Pulmonary artery pressure is determined according to the amount of pulmonary blood flow, pulmonary vascular resistance (PVR), and LA pressure. In general, high LV filling pressure increases pulmonary venous pressure and PASP. In addition, poor LA compliance increases PASP independently of LV filling pressure. 6, 28 These are important factors for postcapillary pulmonary hypertension, and each of them might be age related. Furthermore, individuals with LV dysfunction have a predisposition to develop precapillary pulmonary hypertension. [29] [30] [31] PVR is variable in individuals with LV dysfunction, and previous studies have reported such variability to be independent of LVEF, [31] [32] [33] [34] which further complicates the pathophysiology of pulmonary hypertension in LV dysfunction. Although previous studies have reported that pulmonary hypertension is an important predictor of mortality in HF, 35, 36 the contribution of high ePASP to mortality may differ with age. The present study suggests that the prognostic value of high ePASP in individuals with HF increases with age. It could be that adaptation in right ventricular function in response to high PASP may be different in each person and decrease with age. Further studies are needed to elucidate the mechanisms of the prognostic effect of high ePASP in individuals aged 80 and older with HF.
There are several limitations to the present study. First, it was a retrospective analysis, with all the inherent problems of such a design in proving causality. Second, not all comorbid diseases and conditions associated with mortality could be evaluated, although we tried to include as many potential risk factors as possible. Certain risk or beneficial factors of prognosis were not recorded and analyzed, including data on right ventricular function, LA volume, and an accurate PASP derived using right-sided cardiac catheterization. Likewise, the contribution of left-sided valvular heart disease to pulmonary hypertension 37 was not evaluated, because data on valvular heart disease were not recorded. Finally, it is possible that there were not enough participants to identify all possible risk factors. Several other variables such as hemoglobin and creatinine have been reported as risk factors in previous studies 38, 39 but were not identified in the present study. This might be due to differences not only in participant background and disease conditions, but also in sample size. Nevertheless, the present study was of sufficient size to demonstrate that several prognostic factors, such as high ePASP, discharge medications without diuretics, discharge medications without RAASI, and low SBP at admission, differ significantly between individuals age 80 and older and those younger than 80.
In conclusion, the present study identified high ePASP as an independent risk factor for 1-year mortality in individuals with HF aged 80 and older but not those younger 80. It is therefore possible that PASP could have a greater effect on mortality with age in individuals with HF. Elucidation of the pathophysiological mechanisms behind these findings should facilitate the development of more-effective individualized therapies for older adults with acute HF.
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